[Clozapine treatment: possibilities and limitations].
The purpose of this article--based on the recent years literature--is discussing the principles of the use of clozapine in schizophrenia, with the special attention to treatment-resistance as a main indication, dose selection and duration of the trial. In spite of dynamic development of pharmacotherapy of schizophrenia, clozapine, registered in Europe 25 years ago, still remains a drug of choice in treatment-resistant schizophrenia, that is in 5-25% of patients, bringing a substantial clinical improvement in 30-50% of the group. The main factor limiting the possibility of the use of clozapine is the increased risk of neutropenia and agranulocytosis, what demands the WBC monitoring. Old age and female sex are considered to be potential risk factors. In both classical neuroleptics and clozapine, no clear linear correlation was noticed between the dose and clinical effect. It seems, however, that only in case of clozapine a noticeable correlation exists between the plasma level and clinical improvement. Many authors try to define a threshold level sufficient/necessary to achieve improvement. Suggested amounts are between 250-420 ng/ml. With fixed doses used, extremely different levels of clozapine are observed (from a few, to thousands ng/ml), so measuring plasma level is suggested as a routine procedure in cases of clozapine-resistance. The duration of the trial creates real controversy. Most authors agree that six weeks time, sufficient to diagnose treatment resistance in case of typical neuroleptics, may be too short for clozapine. At the same time, the postulated prolongation of the trial to a few months or even one year, explained by the presence of late improvements, is not well and generally accepted. It seems that time of 2-4 months is in most cases sufficient to notice the potential advantage. The problem of clozapine-resistance still remains open. Many strategies are being proposed (augmentation with lithium, valproate, sulpiride and benzodiazepines), but they demand further examination.
Gmurkowski
K
K
III Kliniki Psychiatrii IPiN w Warszawie.
Szafrański
T
T
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003024:Clozapine